The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Sorry unaware of today’s news on this. Can you please post link? Thanks
I fancy a bounce back to 1800. first level will be company statement refuting the general accusation. then this will just fizzle out. maybe pet insurance will be focused on.
Big 30% drop in sp, due to the forthcoming review of vet prices etc.
Yes was a very positive update and expansion into AUS will be welcomed if they can repeat what has been done in UK.
Market likes todays update…..continued UK investments…hopefully no CMA objections in these as the criteria are known….and expansion into Australia..
As long as they keep expensive debt and costs under control this should continue to grow.
What a pity it does not follow Dechra sp.. Shares would be worth at least 10x more, going back over last decade.
Thanks Ivy, hadnt seen that. Pretty sure that would be it.
Afternoon Razzle,
No idea unless people are linking this with Dechra news but totally unrelated.
Over 8% rise this morning at time of typing. No RNS, no results, anyone know why the leap?
Guess it would have been this https://www.vettimes.co.uk/news/cvs-takeover-of-the-vet-remains-on-hold-amid-competition-concerns/
Gone down with a big hit to-day. Anyone know why.
The trading update highlighted the business is robust…..i would like to see some operational metrics (routine appts, operations, % of pets using regular medicines /treatments)
Inflation adjusted sales would appear to be flatish rather than up 7.5%
The lockdown pets will need increasingly expensive treatment in 6-10 years from now….the current financial issues are going to drag on that but this is a business that can plan for a 10 year customer….
Good company to work for. Poor investment. CVS struggling to stand still sp down and just about fair value
I agree it seems to be sticking around this mark.
Unless more practices are acquired then it may be its mark for a while however those lockdown pets are still around and will need care.
The only other challenge (and this is applys to the majortiy of businesses) is will people cut back. e.g. less jabs, not take when they may have done if pet ill/injured.
A couple of reiterated buy recommendations but no price upgrades since the plan was set out…..seems the market thinks this is about right / high enough at present.
NB is has only been higher during lockdown…..is it just a coincidence a lot of new pets were acquired at that time……
To me this is looking fully valued……other opinions welcomed.
What will the analysts covering the co make of yesterday?
On the one hand doubling adjusted EBITDA sounds like a good thing if it is funded organically and with some debt…..with a limit of 2x EBITDA that could mean put to £400m borrowed….I think that unlikely in the higher interest rate environment but not borrowing will almost certainly delay the plan.
It seems to me management has painted a huge target on their back that they may fail to deliver organically or might borrow and spend unwisely to achieve.
Then there is the valuation question….double EBITDA and 70% cash generation of that means free cash flow of 140m. I think a lot of the growth is already inthe price….
Got out at 17.08 a couple of days back. Small profit but all profit is good profit!!! Will keep an eye here to return.
I know this board is very quiet but been a drop the last few days.
I have got in for a small amount at 15.89.
It seems to drop every few months to this level but gets back 17.5-18 fairly quickly.
joined to try and understand what is happening not a share person . corporate vets still chasing hard to purchase those few independants still out their , yet we are seeing economy having major effect. people suddenly cannot afford treatments having dogs pts on economic grounds and insurance unaffordible. seem mad to sell vet practise with targets on increasing revenue when obviously its tanking.
Not good news. Looks worrying,not surprised the sp took a beating. This company seems like a Football club,better to be a very well paid employee but not a good investment !
CVS Group CEO, Richard Fairman, CFO, Robin Alfonso and COO, Ben Jacklin present the interim results for the period ended 31 December 2021.
Watch the video here: https://www.piworld.co.uk/company-videos/cvs-group-cvsg-interim-results-2022-march-2022/
Or listen to the podcast here: https://piworld.podbean.com/e/cvs-group-cvsg-interim-results-2022-march-2022/
CVS Group, CEO, Richard Fairman summarises the interim results for the period ended 31 December 2021.
Watch the video here: https://www.piworld.co.uk/company-videos/cvs-group-cvsg-2022-interim-results-overview-march-2022/
Or listen to the podcast here: https://piworld.podbean.com/e/cvs-group-cvsg-2022-interim-results-overview-march-2022/
More of the same please for H2.
Interesting to note they have opted not to fight the CMA….the CMA has imposed an arbitrary ceiling of 30% market share….these round numbers plucked out the air by regulators are often wrong but can take years to fight through the courts…..a bigger competitor can do that and the landscape will change again in a few years.
£15 in the next week
confidence today, plenty of buys